IMAGE: Iraneus Ogu, Blockchain and Longevity Consultant at Insilico Medicine, to present "How can AI, big data and blockchain help create better health for all " at the World AI Show, in... view more
Credit: Insilico Medicine
Wednesday, March 13, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery and productive longevity at the World AI Show in Nairobi, Kenya, March 21-22.
The increased availability of data and recent advancements in artificial intelligence present the unprecedented opportunities for healthcare, and major challenges for patients, developers, and providers. The novel deep learning and transfer learning techniques are turning personal data into medical data transforming simple facial pictures and videos into powerful sources of predictive analysis, but depriving patients of the access to their medical records.
The presentation will cover the latest advances in artificial intelligence and blockchain technologies that accelerate the biomedical research and enable patients to control and benefit from their medical data, that might serve as an incentive to undergo constant health monitoring.
"We are happy to present our latest research at the World AI Show, which gathers the leading longevity leaders. The topic of medical data application is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", said Iraneus Ogu, Blockchain and Longevity Consultant at Insilico Medicine, Inc.
World AI Show is a thought-leadership-driven, business-focused, global series of events taking place in strategic locations across the world. The show is part of a world tour that is taking place in Nairobi, Dubai, Singapore, Mauritius, Riyadh and Mumbai this year. The conference connects top AI experts, enterprises, government representatives, data scientists, technology leaders, startups, investors, researchers, academicians, and global AI innovators.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
For further information, images or interviews, please contact:
Contact: Polina Firsanova
ai@pharma.ai
Website: http://insilico.com/
Official website of the conference: https://nairobi.worldaishow.com/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
